Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases.
Our lead product candidate, AKB-9778, is a Tie2 activator being developed for the treatment of diabetic eye disease. AKB-9778 is currently in a Phase 2b study (TIME-2b) for the treatment of non-proliferative diabetic retinopathy (NPDR), a disease that affects millions of people across the globe.
Vascular stabilization by activation of the Tie2 pathway is of high interest in multiple indications, including several retinopathies. Aerpio is a leader in this area and is developing first in class treatments for ocular diseases based on novel therapeutics targeting vascular endothelial-protein tyrosine phosphatase (VE-PTP), a key negative regulator of the Tie2 pathway in vascular endothelial cells.
In contrast to current therapies, which require repeated injections into the eye, AKB-9778 is being developed as a patient self-administered, subcutaneous injection, similar to insulin. A randomized, multi-center, placebo-controlled Phase 2b study (TIME-2b) of AKB-9778 in patients with NPDR is currently on-going.
The second program in development builds on our innovative approach to targeting the Tie2 pathway. ARP-1536 is a humanized monoclonal antibody that works by binding the extracellular domain of VE-PTP inhibiting its ability to interact with the Tie2 receptor. This prevents the inactivation of Tie2 and promotes vascular stability.
ARP-1536 is in pre-clinical development. We plan on developing ARP-1536 in combination with anti-VEGF therapy for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME)
AKB-4924 is a unique small molecule inhibitor of prolyl-hydroxylase domain enzymes (PHDs). PHDs are key regulators of hypoxia inducible factor-1 alpha (HIF-1 alpha) which, when dysregulated, has been shown to exacerbate inflammation and disrupt intestinal epithelial barrier function.
By inhibiting PHDs, AKB-4924 stabilizes HIF-1 alpha leading to resolution of inflammation and restoration of epithelial barrier function. AKB-4924 is in Phase 1 clinical development and we plan on developing it as a once-daily, oral treatment for inflammatory bowel disease (IBD).